BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 34160821)

  • 1. Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
    Gilreath J; Lo M; Bubalo J
    Drugs; 2021 Jul; 81(11):1285-1305. PubMed ID: 34160821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
    Al-Samkari H; Jiang D; Gernsheimer T; Liebman H; Lee S; Wojdyla M; Vredenburg M; Cuker A
    Br J Haematol; 2022 May; 197(3):359-366. PubMed ID: 35179784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
    Kuter DJ; Macahilig C; Grotzinger KM; Poston SA; Wang PF; Dawson KL; Ward M
    Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.
    Al-Samkari H; Kuter DJ
    Am J Hematol; 2018 Dec; 93(12):1501-1508. PubMed ID: 30187942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.
    Al-Samkari H; Kuter DJ
    Br J Haematol; 2018 Oct; 183(2):168. PubMed ID: 29978577
    [No Abstract]   [Full Text] [Related]  

  • 8. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
    Atkinson K
    Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies.
    Maan R; de Knegt RJ; Veldt BJ
    Drugs; 2015 Nov; 75(17):1981-92. PubMed ID: 26501978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres.
    Lakhwani S; Perera M; Fernández-Fuertes F; Ríos de Paz MA; Torres M; Raya JM; Hernández MT
    Eur J Haematol; 2017 Oct; 99(4):372-377. PubMed ID: 28759125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus.
    Pulanić D; Bátorová A; Bodó I; Červinek L; Ionita I; Lissitchkov T; Melikyan A; Podolak-Dawidziak M
    Ann Hematol; 2023 Apr; 102(4):715-727. PubMed ID: 36826482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
    Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
    Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
    Dodillet H; Kreuzer KA; Monsef I; Skoetz N
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.
    Kuter DJ
    Blood Rev; 2022 May; 53():100909. PubMed ID: 34815110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombopoietin receptor agonists: ten years later.
    Ghanima W; Cooper N; Rodeghiero F; Godeau B; Bussel JB
    Haematologica; 2019 Jun; 104(6):1112-1123. PubMed ID: 31073079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
    Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
    Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia.
    Song AB; Al-Samkari H
    Expert Rev Clin Immunol; 2022 Aug; 18(8):783-791. PubMed ID: 35793401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.
    Neunert C; Despotovic J; Haley K; Lambert MP; Nottage K; Shimano K; Bennett C; Klaassen R; Stine K; Thompson A; Pastore Y; Brown T; Forbes PW; Grace RF;
    Pediatr Blood Cancer; 2016 Aug; 63(8):1407-13. PubMed ID: 27135461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia.
    Lozano ML; Mingot-Castellano ME; Perera MM; Jarque I; Campos-Alvarez RM; González-López TJ; Carreño-Tarragona G; Bermejo N; Lopez-Fernandez MF; de Andrés A; Valcarcel D; Casado-Montero LF; Alvarez-Roman MT; Orts MI; Novelli S; Revilla N; González-Porras JR; Bolaños E; Rodríguez-López MA; Orna-Montero E; Vicente V
    Sci Rep; 2019 Nov; 9(1):16680. PubMed ID: 31723222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.